Okogen

Okogen is an ophthalmic specialty pharmaceutical company dedicated to developing innovative therapies for the treatment of ocular diseases. We focus on addressing the root causes of these conditions rather than merely treating their symptoms. Our lead product candidate, OKG-0301, is currently in development for the treatment of viral conjunctivitis (commonly known as "pink eye"), a viral infection that affects approximately 30 million people worldwide each year and currently has no approved treatments.